Fernanda Motta R. da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fernanda Motta R. da Silva has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Newton Gonçalves Castro
Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
4 shared publications - Alexandre Giusti-Paiva
Departamento de Ciências Fisiológicas, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil
2 shared publications Andrea Tarozzi
Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Rimini 47921, Italy
2 shared publications- Claudio Viegas
Universidade Federal de Alfenas, Instituto de Química, Laboratório de Pesquisa em Química Medicinal (PeQuiM), Alfenas, Minas Gerais, Brazil
2 shared publications - Gilda Angela Neves
Laboratório de Farmacologia Molecular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
2 shared publications - Isabella Alvim Guedes
National Laboratory for Scientific Computing, Molecular Modeling in Biological Systems Group, Petrópolis 25651-075, RJ, Brazil
2 shared publications
Latest Publications
- 1 April 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 130, 440-457
Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease
- 1 April 2017
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 130, 440-457
Design, synthesis and evaluation of novel feruloyl-donepezil hybrids as potential multitarget drugs for the treatment of Alzheimer's disease
- 1 January 2016
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 108, 687-700
Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease
- 1 January 2016
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 108, 687-700
Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease
- 1 November 2015
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 31 (6) , 1069-1078
Design, synthesis, and evaluation of guanylhydrazones as potential inhibitors or reactivators of acetylcholinesterase
Analogs of pralidoxime, which is a commercial antidote for intoxication from neurotoxic organophosphorus compounds, were designed, synthesized, characterized, and tested as potential inhibitors or reactivators of acetylcholinesterase (AChE) using the Ellman’s test, nuclear magnetic resonance, and molecular modeling. These analogs include 1-methylpyridine-2-carboxaldehyde hydrazone, 1-methylpyridine-2-carboxaldehyde guanylhydrazone, and six other guanylhydrazones obtained from different benzaldehydes. The results indicate that all compounds are weak AChE reactivators but relatively good AChE inhibitors. The most effective AChE inhibitor discovered was the guanylhydrazone derived from 2,4-dinitrobenzaldehyde and was compared with tacrine, displaying similar activity to this reference material. These results indicate that guanylhydrazones as well as future similar derivatives may function as drugs for the treatment of Alzheimer's disease.
- 1 November 2015
- Published by Taylor & Francis in Journal of Enzyme Inhibition and Medicinal Chemistry
- Vol. 31 (6) , 1069-1078
Design, synthesis, and evaluation of guanylhydrazones as potential inhibitors or reactivators of acetylcholinesterase
Analogs of pralidoxime, which is a commercial antidote for intoxication from neurotoxic organophosphorus compounds, were designed, synthesized, characterized, and tested as potential inhibitors or reactivators of acetylcholinesterase (AChE) using the Ellman’s test, nuclear magnetic resonance, and molecular modeling. These analogs include 1-methylpyridine-2-carboxaldehyde hydrazone, 1-methylpyridine-2-carboxaldehyde guanylhydrazone, and six other guanylhydrazones obtained from different benzaldehydes. The results indicate that all compounds are weak AChE reactivators but relatively good AChE inhibitors. The most effective AChE inhibitor discovered was the guanylhydrazone derived from 2,4-dinitrobenzaldehyde and was compared with tacrine, displaying similar activity to this reference material. These results indicate that guanylhydrazones as well as future similar derivatives may function as drugs for the treatment of Alzheimer's disease.